Protocol Ledger

NCT05179057 · Phase III · TERMINATED

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Interventional Phase III clinical trial protocol NCT05179057 sponsored by AlloVir in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-26 Enrollment: 57 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05179057
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)57 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05179057
Protocol FieldVerified Registry Value
NCT IdentifierNCT05179057
Consolidated Lead SponsorAlloVir
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment57 participants (ACTUAL)
Registered Start Date2022-04-26
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI